Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	FLT3 exon 14 ins JAK3 V722I
Gene Variant Detail	FLT3 exon 14 ins (gain of function - predicted) JAK3 V722I (gain of function)
Relevant Treatment Approaches

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 9 of 9 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FLT3 exon 14 ins JAK3 V722I	acute myeloid leukemia	predicted - resistant		Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with acute myeloid leukemia harboring a FLT3-ITD mutation treated with Nexavar (sorafenib) was found to have acquired a JAK3 V722I mutation with a variant allele frequency of 49% upon relapse (PMID: 33149267).	33149267
FLT3 exon 14 ins JAK3 V722I	hematologic cancer	sensitive		Midostaurin + Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Rydapt (midostaurin) and Jakafi (ruxolitinib) inhibited downstream signaling and cell growth in transformed hematologic cells expressing aa FLT3-ITD mutation and JAK3 V722I in culture (PMID: 33149267).	33149267
FLT3 exon 14 ins JAK3 V722I	hematologic cancer	sensitive		Gilteritinib + Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xospata (gilteritinib) and Jakafi (ruxolitinib) inhibited growth of transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I in culture (PMID: 33149267).	33149267
FLT3 exon 14 ins JAK3 V722I	hematologic cancer	resistant		Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I were resistant to treatment with Rydapt (midostaurin) in culture (PMID: 33149267).	33149267
FLT3 exon 14 ins JAK3 V722I	hematologic cancer	resistant		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I were resistant to treatment with Xospata (gilteritinib) in culture (PMID: 33149267).	33149267
FLT3 exon 14 ins JAK3 V722I	hematologic cancer	resistant		Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I were resistant to treatment with Jakafi (ruxolitinib) in culture (PMID: 33149267).	33149267
FLT3 exon 14 ins JAK3 V722I	hematologic cancer	resistant		Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I were resistant to treatment with Xeljanz (tofacitinib) in culture (PMID: 33149267).	33149267
FLT3 exon 14 ins JAK3 V722I	hematologic cancer	sensitive		Midostaurin + Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Rydapt (midostaurin) and Xeljanz (tofacitinib) inhibited cell growth and downstream signaling of transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I in culture (PMID: 33149267).	33149267
FLT3 exon 14 ins JAK3 V722I	hematologic cancer	decreased response		Pacritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vonjo (pacritinib) treatment decreased cell proliferation and Akt and Erk phosphorylation, but did not fully inhibit Stat5 phosphorylation in transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I and was less effective compared to treatment with the combination of a FLT3 inhibitor and a JAK inhibitor in culture (PMID: 33149267).	33149267

Showing 1 to 9 of 9 entries

Filter rows: